Novel small molecule new chemical entities for the treatment of autoimmune, inflammatory diseases

Azora Therapeutics is focused on developing innovative small molecule therapies aimed at treating autoimmune and inflammatory diseases by harnessing the body's natural immune regulation. Central to their approach is the activation of the Aryl Hydrocarbon Receptor (AhR), which is influenced by naturally occurring agonists produced by healthy microbiota in the skin and colon. This activation is crucial for maintaining immune balance, as it has been linked to reduced T-helper 17 activity and enhanced differentiation of T-regulatory cells, which are essential for regulating inflammatory responses and improving barrier function. Azora's formulations are specifically designed to locally activate AhR, thereby rebalancing immune responses to address conditions such as inflammatory bowel disease, psoriasis, and hidradenitis suppurativa.

The company leverages decades of expertise in drug development, with a leadership team that has contributed to the creation of significant therapeutic agents. Their research emphasizes the importance of AhR signaling in the context of inflammatory diseases, highlighting how defects in this pathway can lead to disease progression. By targeting the AhR, Azora Therapeutics aims to develop effective treatments that can mitigate the symptoms and underlying causes of serious inflammatory conditions, ultimately improving patient outcomes.

United States

Azora Therapeutics is a pharmaceutical development company developing novel therapies for serious autoinflammatory diseases like hidradenitis suppurativa.

Azora Therapeutics

Company Details